Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis
Author:
Publisher
Springer Science and Business Media LLC
Subject
Nephrology
Link
http://link.springer.com/article/10.1007/s40620-017-0419-5/fulltext.html
Reference64 articles.
1. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316(2):73–78. doi: 10.1056/nejm198701083160203 (Epub 1987/01/08)
2. Fishbane S (2009) Anemia in chronic kidney disease: status of new therapies. Curr Opin Nephrol Hypertens 18(2):112–115. doi: 10.1097/MNH.0b013e328324b672 (Epub 2009/05/13)
3. Macdougall IC, Ashenden M (2009) Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications. Adv Chronic Kidney Dis 16(2):117–130. doi: 10.1053/j.ackd.2008.12.010 (Epub 2009/02/24)
4. Macdougall IC, Hutton RD, Cavill I, Coles GA, Williams JD (1990) Treating renal anaemia with recombinant human erythropoietin: practical guidelines and a clinical algorithm. BMJ 300(6725):655–659 (Epub 1990/03/10)
5. Fishbane S, Shah HH (2015) The emerging role of biosimilar epoetins in nephrology in the United States. Am J Kidney Dis Off J Natl Kidney Found 65(4):537–542. doi: 10.1053/j.ajkd.2014.11.018 (Epub 2015/01/15)
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-02-13
2. Anämien;Arzneiverordnungs-Report 2023;2023
3. Anämien;Arzneiverordnungs-Report 2022;2022
4. Comparative Efficacy and Safety Study of Darbepoetin Alfa versus Epoetin Alfa in Management of Anemia Associated with ESRD in Egyptian Hemodialysis Patients;Current Drug Safety;2021-11-23
5. COST-MINIMIZATION ANALYSIS OF USING SHORT AND LONG-ACTING ERYTHROPOESIS-STIMULATING AGENTS FOR CORRECTION OF NEPHROGENIC ANEMIA AGAINST THE BACKGROUND OF SUBSTITUTION THERAPY;Pharmacy & Pharmacology;2021-10-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3